Center for Evidence-based Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Beitou District, Taipei, 112, Taiwan, Republic of China.
Divison of Faculty Development, Taipei Veterans General Hospital, Taipei, Taiwan.
Trials. 2019 May 10;20(1):265. doi: 10.1186/s13063-019-3366-8.
Home blood pressure (BP) and unattended automated BP (uAOBP) monitoring have been recommended by guidelines for the care of hypertensive subjects. However, BP measurements in the peripheral arteries cannot serve as direct substitutes for their central counterparts. Moreover, the comparative effectiveness and safety of BP-guided strategies using these BP measuring devices have never been evaluated.
METHODS/DESIGN: Patients with uncontrolled or newly diagnosed hypertension aged 20-90 years will be recruited via outpatient clinics and allocated into three arms by stratified randomization (baseline systolic BP 130-155 mmHg and 155-180 mmHg): home BP, uAOBP, and central BP-guided treatment. At each scheduled visit to the clinic, a patient's BP will be measured by each of the three methods of measuring BP. The blood pressure from three different methods will be confirmed available at each visit. Patients and physicians will be blinded to the allocated interventions because they will use measured BP values in the clinic through a standardized report format. A common BP target for systolic blood pressure (SBP) of 130 mmHg is adopted for these BP-guided strategies. The primary outcome is the change of 24-h mean ambulatory SBP at 3 months. A key secondary outcome is to determine the percentage achieving their target BPs at 3 months and the decrease of left ventricular mass at 12 months.
To our knowledge, this is the first prospective double-blind randomized controlled trial to assess the optimal guiding strategy for hypertension. It will help to define which BP monitoring method is the most effective for guiding the clinical management of hypertension. It will provide good evidence to support future guideline recommendations for BP monitoring devices.
ClinicalTrials.gov, NCT03578848 . Registered on 4 June 2018.
家庭血压(BP)和无人值守的自动 BP(uAOBP)监测已被指南推荐用于高血压患者的护理。然而,外周动脉的 BP 测量不能直接替代其中心对应物。此外,使用这些 BP 测量设备的 BP 指导策略的比较效果和安全性从未得到过评估。
方法/设计:将通过门诊诊所招募年龄在 20-90 岁之间的未控制或新诊断的高血压患者,并通过分层随机化(基线收缩压 130-155mmHg 和 155-180mmHg)将其分为三组:家庭 BP、uAOBP 和中心 BP 指导治疗。在每次预约门诊时,将通过三种 BP 测量方法中的每一种测量患者的 BP。每次就诊时都会确认三种不同方法的 BP 都可用。由于患者和医生将通过标准化报告格式在诊所中使用测量的 BP 值,因此他们将对分配的干预措施保持盲目。这些 BP 指导策略采用了收缩压(SBP)的共同目标值 130mmHg。主要结局是 3 个月时 24 小时平均动态 SBP 的变化。一个关键的次要结局是确定 3 个月时达到目标 BP 的百分比和 12 个月时左心室质量的减少。
据我们所知,这是第一项评估高血压最佳指导策略的前瞻性双盲随机对照试验。它将有助于确定哪种 BP 监测方法最有效地指导高血压的临床管理。它将为未来的 BP 监测设备指南建议提供良好的证据支持。
ClinicalTrials.gov,NCT03578848。于 2018 年 6 月 4 日注册。